NCT00342628View on ClinicalTrials.gov

Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants

PHASE2CompletedINTERVENTIONAL
Enrollment

301

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

January 31, 2011

Conditions
Typhoid Fever
Interventions
BIOLOGICAL

Vi-rEPA conjugate vaccine for typhoid fever

Vi-rEPA contains a 25 ug/dose of Vi (Sanofi-Pasteur Lot 130) and rEPA in 0.2 N NaCl, 10 mM phosphate PH 7.2 and 0.01% thimerosal.

BIOLOGICAL

Hib-TT

Hib-TT is Hemophilus influenzae type b-tetanus toxoid conjugate vaccine (ActHib, NDC#49281-545-05 Sanofi-Pasteur, France) in single-dose vials containing 10 ugof Hib CP conjugated to 24 ug of tetanus toxoid

BIOLOGICAL

DTP

DTP, diphtheria, tetanus toxoid and pertussis vaccine were from the Ministry of Health, Vietnam for routine infant immunization

Trial Locations (1)

Unknown

Thanh Thuy District Health Center, Việt Trì

All Listed Sponsors
lead

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

NCT00342628 - Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants | Biotech Hunter | Biotech Hunter